Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tylenol Arthritis Extended Relief Caplets

This article was originally published in The Tan Sheet

Executive Summary

McNeil relaunching Tylenol Extended Relief under new name; the renamed acetaminophen product, slated to ship before August, was promoted to the trade at the NACDS Marketplace show in Philadelphia June 28-July 1. Original Tylenol Extended Relief, marketed under an approved NDA, was introduced in 1994. The analgesic contains 650 mg acetaminophen and employs a bi-layer system for the eight-hour time-release mechanism. Indications on a label mock-up read: "For the temporary relief of the minor pain of arthritis, and the temporary relief of minor aches and pains associated with the common cold, headache, toothache, muscular aches, backache, for the pain of menstrual cramps and for the reduction of fever." The product is not covered by Waxman/Hatch exclusivity; several patents covering "oral sustained release acetaminophen formulation and process" expire in 2007. Tylenol Extended Relief is sold in three SKUs: a 24-count retails for about $3.70, a 50-count for $5.70 and a 100-tablet bottle for about $8.40. The repositioning appears to follow a growing trend toward indication specific OTCs; Bristol-Myers Squibb recently introduced Excedrin Migraine for relief of mild to moderate pain associated with migraine headache ("The Tan Sheet" Jan. 19, pp. 1-5)...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS088635

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel